Dengue Vaccine Updates - Brazil & Global
Table of Contents
Glance: Recent approvals and data reinforce the growing availability and effectiveness of dengue vaccines. Brazil’s Anvisa approved the Butantan vaccine, while Qdenga demonstrates long-lasting protection even in those without prior infection. Questions remain regarding accessibility and suitability for all age groups.
Key Facts
- What: multiple dengue vaccines are nearing wider availability, including Butantan (Brazil) and Qdenga (globally).
- Where: Brazil (Butantan approval), Global (Qdenga data & availability).
- When: February 2024 (Anvisa approval), ongoing data releases for Qdenga.
- Why it Matters: Dengue fever is a significant public health threat, especially in tropical and subtropical regions. Vaccines offer a crucial preventative measure.
- What’s Next: Rollout of the Butantan vaccine in Brazil, continued monitoring of Qdenga’s effectiveness, and addressing questions about vaccine access and eligibility.
vaccine Details
| Vaccine Name | Developer/Manufacturer | Type | Approval Status (as of Feb 2024) | Key Features |
|---|---|---|---|---|
| Butantan | Butantan Institute (Brazil) | Live attenuated | Approved by Anvisa (Brazil) | First dengue vaccine developed entirely in Brazil. |
| Qdenga | Takeda | Live attenuated | Approved in Europe, Indonesia, Thailand, Australia, and others. | Demonstrated long-lasting protection, effective even in those *without* prior dengue infection. |
Frequently asked Questions (Brazil Focus)
- Is the dengue vaccine free? Availability of free vaccination will depend on public health programs and government funding.
- Can elderly people take it? This requires medical evaluation. Current recommendations may vary based on individual health conditions.
sources: